Sheba Medical Center's innovation arm, Accelerate, Redesign, and Collaborate (ARC), has partnered with Roche to advance the diagnosis and treatment of non-small cell lung cancer (NSCLC) by leveraging AI.
This collaboration aims to integrate AI with digital pathology tools to enhance the speed and accuracy of NSCLC diagnostics.
Formalised at the 2024 ARC Summit, the partnership will see the co-development of digital pathology solutions on Roche's navify Digital Pathology platform.
The goal is to improve the detection of molecular markers in NSCLC, which is expected to lead to faster and more precise detection of patients suitable for targeted treatments and immunotherapies.
This solution significantly minimises the time from diagnosis to treatment and could save lives, thereby enabling oncologists to act quickly and with greater certainty.
Roche’s navify platform will be used to develop integrated algorithms that can detect biomarkers and predict patient responses to certain treatments.
Initially focusing on NSCLC, the partnership plans to expand these progressions to other tumours and diseases in the future.
It leverages Sheba’s digital pathology expertise and the clinical decision support capabilities of Roche, underscoring a joint dedication to enhancing personalised medicine.
Sheba Medical Center director-general Prof Yitshak Kreiss said: “This collaboration marks an exciting moment in our efforts to transform healthcare on a global scale. When one of the world’s leading digital pathology providers teams up with Sheba’s leading innovators in AI-driven diagnostics, it’s not just a statement of intent; it’s the start of a groundbreaking journey.
“Together, we will be able to advance patient care in ways that were previously unimaginable. This collaboration will help us leverage advanced technologies to create new benchmarks for diagnostic accuracy and treatment efficacy.”
Recently, Roche secured CE mark approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, for the identification of epithelial ovarian cancer (EOC) individuals suitable for targeted therapy with AbbVie’s ELAHERE (mirvetuximab soravtansine).
